Koscielny V[au] - Search Results

Year	Number of Results
2011	1
2015	1
2016	3
2018	1
2020	1
2021	1
2024	2

1

Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex^®) in reducing annualized relapse rates and MRI brain lesions.

Koscielny V. Koscielny V. Neurodegener Dis Manag. 2018 Jun;8(3):141-142. doi: 10.2217/nmt-2018-0012. Neurodegener Dis Manag. 2018. PMID: 29943693 Free article.

2

Understanding remission in real-world lupus patients across five European countries.

Schneider M, Mosca M, Pego-Reigosa JM, Hachulla E, Teh LS, Perna A, Koscielny V, Pike J, Lobosco S, Apolone G. Schneider M, et al. Among authors: koscielny v. Lupus. 2016 Apr;25(5):505-12. doi: 10.1177/0961203315619030. Epub 2015 Dec 2. Lupus. 2016. PMID: 26635245

3

Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.

Augustin M, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, Radtke MA, Bundy C, Mellars L, Greggio C, Cordey M, Koscielny V, Griffiths CEM. Augustin M, et al. Among authors: koscielny v. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):123-134. doi: 10.1111/jdv.16431. Epub 2020 Jul 30. J Eur Acad Dermatol Venereol. 2021. PMID: 32279378

4

INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study.

Graber E, Baldwin HE, Fried RG, Rieder EA, Hebert AA, Del Rosso J, Kircik L, Stein Gold L, Harper JC, Alexis AF, Narayanan S, Koscielny V, Kasujee I. Graber E, et al. Among authors: koscielny v. J Drugs Dermatol. 2024 Feb 1;23(2):SF405634s5-SF405634s11. doi: 10.36849/JDD.SF405634. J Drugs Dermatol. 2024. PMID: 38306151

5

INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study.

Baldwin HE, Graber E, Harper JC, Alexis AF, Stein Gold L, Kircik L, Del Rosso J, Hebert AA, Rieder EA, Fried RG, Narayanan S, Koscielny V, Kasujee I. Baldwin HE, et al. Among authors: koscielny v. J Drugs Dermatol. 2024 Feb 1;23(2):SF405634s12-SF405634s18. doi: 10.36849/JDD.SF405634. J Drugs Dermatol. 2024. PMID: 38306152

6

Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation.

Wade AG, Crawford GM, Pumford N, Koscielny V, Maycock S, McConnachie A. Wade AG, et al. Among authors: koscielny v. BMC Med Res Methodol. 2011 Jun 14;11:91. doi: 10.1186/1471-2288-11-91. BMC Med Res Methodol. 2011. PMID: 21672203 Free PMC article.

7

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.

Collins CE, Dall'Era M, Kan H, Macahilig C, Molta C, Koscielny V, Chang DJ. Collins CE, et al. Among authors: koscielny v. Lupus Sci Med. 2016 Jan 11;3(1):e000118. doi: 10.1136/lupus-2015-000118. eCollection 2016. Lupus Sci Med. 2016. PMID: 26835146 Free PMC article.

8

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.

Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, Perna A, Cholmakow-Bodechtel C, Koscielny VB, Carnarius H. Schwarting A, et al. Among authors: koscielny vb. Rheumatol Ther. 2016 Dec;3(2):271-290. doi: 10.1007/s40744-016-0047-x. Epub 2016 Nov 1. Rheumatol Ther. 2016. PMID: 27804088 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year